Skip to main content
. 2021 Feb 25;11(9):4281–4297. doi: 10.7150/thno.51193

Figure 1.

Figure 1

Antitumor effect of TRAIL proteins in mice bearing tumor grafts of CRC cells. A. Characterization of TRAIL proteins. IgBD-TRAIL was produced by fusing the IgG-binding domain (IgBD) to the N-terminus of TRAIL. Binding of IgBD-TRAIL to mIgG was analyzed by SEC. The difference in blood clearance of IgBD-TRAIL and TRAIL was reflected by the time-dependent reduction in cell death induced by the residual proteins in plasma (diluted 25, 50 and 250 times). B. Expression of DR4 and DR5. The percentages of the death receptor-positive cells are indicated. C. Cytotoxicity of TRAIL proteins. D. Antitumor effect of a single dose of TRAIL proteins administered at day 0 in mice (N=5-6) bearing tumor grafts of COLO 205, LS174T or HT29 cells. COLO 205 tumor grafts were treated with 3 mg/kg IgBD-TRAIL (IgBD-TRAIL-3) or 10 mg/kg TRAIL (TRAIL-10). The mice bearing LS174T or HT29 tumor grafts were treated with 10 mg/kg of TRAIL proteins.